IQVIA Holdings Inc. (NYSE:IQV) Position Increased by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 12.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 8,361 shares of the medical research company’s stock after acquiring an additional 900 shares during the period. E. Ohman J or Asset Management AB’s holdings in IQVIA were worth $1,643,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently added to or reduced their stakes in the stock. Capital Performance Advisors LLP bought a new stake in IQVIA in the 3rd quarter valued at about $27,000. Park Place Capital Corp bought a new stake in shares of IQVIA during the third quarter valued at approximately $28,000. Synergy Asset Management LLC bought a new position in IQVIA in the 4th quarter worth approximately $33,000. Avior Wealth Management LLC increased its position in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares during the period. Finally, Assetmark Inc. boosted its position in IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on IQV shares. Truist Financial reduced their price objective on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a report on Thursday, December 12th. Redburn Atlantic started coverage on shares of IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Stephens began coverage on IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 price target on the stock. Finally, William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $254.53.

IQVIA Stock Performance

Shares of NYSE IQV opened at $200.00 on Wednesday. The company has a market capitalization of $36.30 billion, a P/E ratio of 26.25, a price-to-earnings-growth ratio of 2.15 and a beta of 1.48. The business’s 50-day moving average price is $200.31 and its two-hundred day moving average price is $220.14. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.